Gevorg Tamamyan: Albania’s Vision for the Future of Pediatric Oncology
Gevorg Tamamyan, Editor-in-Chief of OncoDaily, and the President of SIOP Asia and POEM Group, shared a post on LinkedIn:
“Beautiful country. Beautiful people.
Even this short trip was enough to truly feel Albania. A wonderful nation hidden between green mountains and mighty sea waves.
A warm country; one that stays warm even on a freezing day, thanks to the inner warmth and genuine smiles of its beautiful people.
So much energy. So much passion. So much life.
Though small in size, Albania generates enormous positive energy.
And they have amazing plans and powerful aspirations to make Albania a top destination for pediatric oncology.
A place where compassionate, comprehensive care walks hand in hand with scientific breakthroughs.
For every child with cancer. For every family.
There is a clear vision. A concrete plan for the coming years. And I am confident they will make it happen.
Great people. Great leaders. Great doers.
Thank you for the warm hospitality and for sharing your inspiring vision.
The best is yet to come.
P.S. And they have a great food. ”

Other posts featuring Gevorg Tamamyan on Hemostasis Today.
-
Feb 23, 2026, 15:54Alan Nurden: From Early Discoveries to New Therapeutic Advances in von Willebrand Disease
-
Feb 23, 2026, 15:36Simon Senanu: The Peripheral Blood Smear as an Essential Diagnostic Tool in Modern Medicine
-
Feb 23, 2026, 15:32Cheng-Hock Toh: The Paradox of Hematology
-
Feb 23, 2026, 15:20Rabab Al Dawood: Moderating the Coagulation and Hemostasis Session at the ISLH 1st Joint Conference
-
Feb 23, 2026, 15:16Amira Khater: Key Updates on Pulmonary Embolism Management from AHA and ACC Guidelines
-
Feb 23, 2026, 14:45Stacey McGeown: Rare Disease Awareness Day at QUB Marks the Start of Rare Disease Month
-
Feb 23, 2026, 13:53Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 1
-
Feb 23, 2026, 13:02Deepak Yadav: What 2025 Evidence Tells Us About Stroke Care
-
Feb 23, 2026, 12:55Radoslaw Kaczmarek: Will AAV Gene Therapy for Hemophilia Trigger Tumorigenesis?